- Home
- VRE vs CRVS Comparison
VRE vs CRVS Comparison
Compare VRE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRE | CRVS |
|---|---|---|
| Founded | 1949 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VRE | CRVS |
|---|---|---|
| Price | $18.87 | $15.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $18.67 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 01-01-0001 | 06-26-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 420.00 | 48.04 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $288,434,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | $23.60 | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $13.69 | $2.54 |
| 52 Week High | $18.89 | $26.95 |
Technical Indicators
Market Signals| Indicator | VRE | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 79.53 | 39.50 |
| Support Level | $14.43 | $6.65 |
| Resistance Level | $18.89 | $18.73 |
| Average True Range (ATR) | 0.03 | 0.98 |
| MACD | -0.08 | -0.36 |
| Stochastic Oscillator | 66.67 | 14.19 |
Price Performance
Historical ComparisonAbout VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).